Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B13 | Q7Z5P4 | 2/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30448891 | 1.00 | BRPF1 (0.40) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL3099860 | 0.78 | BRPF1 (0.40) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL9367162 | 0.76 | CA12 (0.50) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL28980751 | 0.74 | BRPF1 (0.37) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL21820292 | 0.73 | CDK4 (0.33) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL3346855 | 0.73 | CYP1A2 (0.36) | MAPTHSD17B13ERN1 | |
| SCHEMBL22490611 | 0.73 | NQO2 (0.51) | KAT2BBRD9MAPTHIF1A | |
| SCHEMBL30449477 | 0.73 | NQO2 (0.51) | KAT2BBRD9MAPTHIF1A | |
| SCHEMBL3374251 | 0.73 | HSD17B13 (0.33) | MAPTHSD17B13 | |
| SCHEMBL30448309 | 0.73 | CYP1A2 (0.36) | MAPTHSD17B13ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111527093-B | Antibacterial heterocyclic compounds and synthesis thereof | 巴格沃克斯研究有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | Bugworks Research, Inc. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | Bugworks Research, Inc. | 2021-03-11 | — | — | US | disclosed |
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | Bugworks Research, Inc. | 2021-03-11 | — | — | US | disclosed |
| EP-3717490-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | Bugworks Research, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111527093-A | Antibacterial heterocyclic compounds and synthesis thereof | 巴格沃克斯研究有限公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2010046388-A1 | SUBSTITUTED (AZA) -1-METHYL-1H-QUINOLIN-2-ONES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010045987-A1 | SUBSTITUTED (AZA) -1-METHYL-1H-QUIN0LIN-2-0NES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070772-A1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | HLA-B, BAX, REN | BRPF1 4131/4885CA12 2222/4885BRD4 3129/4885 |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | HLA-B, BAX, REN | BRPF1 4131/4885CA12 2222/4885BRD4 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.